Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026)
Compugen's (CGEN) quarterly Non-Current Deffered Revenue came in at $22.1 million in Q1 2026, down 30.31% year-on-year from $31.8 million in Q1 2025, and down 11.24% quarter-over-quarter from $24.9 million in Q4 2025.
Compugen (CGEN) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Compugen has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $22.1 million for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $22.1 million, down 30.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 million (down 30.31% YoY), and the FY2025 annual result was $24.9 million, down 26.74% from the prior year.
- Non-Current Deffered Revenue came in at $22.1 million for Q1 2026 at Compugen, down from $24.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $34.0 million in Q4 2024 to a low of $21.0 million in Q2 2024.
- The 4-year median for Non-Current Deffered Revenue is $26.5 million (2023), against an average of $26.9 million.
- Across the five-year window, Non-Current Deffered Revenue jumped 40.73% in 2025 and slumped 30.31% in 2026, its largest moves.
- Compugen's Non-Current Deffered Revenue stood at $25.4 million in 2023, then soared by 34.08% to $34.0 million in 2024, then fell by 26.74% to $24.9 million in 2025, then retreated by 11.24% to $22.1 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $22.1 million (Q1 2026), $24.9 million (Q4 2025), and $27.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | 22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.14 Mn |
| Dec 31, 2025 | 24.94 Mn |
| Sep 30, 2025 | 27.57 Mn |
| Jun 30, 2025 | 29.59 Mn |
| Mar 31, 2025 | 31.77 Mn |
| Dec 31, 2024 | 34.05 Mn |
| Sep 30, 2024 | 29.24 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Mar 31, 2024 | 23.23 Mn |
| Dec 31, 2023 | 25.39 Mn |
| Dec 31, 2013 | 1.45 Mn |